Publications by authors named "Alexandra Audemard-Verger"
Article Synopsis
- * It typically affects Caucasians equally across genders and can also be associated with other autoimmune diseases like polyarteritis nodosa.
- * While ocular symptoms often have a good prognosis with potential recovery of vision, cochleo-vestibular issues can lead to serious and irreversible hearing loss, and treatment options are not well-established due to the condition's rarity.
Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy.
Cancer Immunol Res
September 2024
Article Synopsis
- Cancers evade the immune system, and effective immunotherapies, especially those targeting PD1, work by enhancing T-cell functions, particularly IFNγ production.
- While immunotherapies have improved patient outcomes, not everyone responds, necessitating alternative treatments to enhance their effectiveness.
- The study shows that iron supplementation boosts T-cell responses and enhances the effectiveness of anti-PD1 therapy in mice, indicating that combining iron with immunotherapy could improve cancer treatment outcomes.
Introduction: IgA vasculitis diagnosis relies primarily on clinical features and is confirmed by pathological findings. To date, there is no reliable noninvasive diagnostic biomarker.
Objective: We aimed to explore the baseline serum metabolome of adult patients with IgA vasculitis to identify potential diagnostic biomarkers.
ADULT IGA VASCULITIS. IgA vasculitis previously named rheumatoid purpura is a rare systemic vasculitis in adults involving small vessels and associated with the presence of immunoglobulin A deposits. IgA vasculitis is often triggerd by infections, taking medication and vaccination.
View Article and Find Full Text PDFIntroduction: This study aimed to provide an updated analysis of the different prognostic trajectories of patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibodies.
Methods: Among a cohort of 70 patients, baseline characteristics and phenotypes, treatments and outcomes were analyzed. A Cox proportional hazards model was used to identify factors associated with poor outcomes, i.
Objectives: Adult IgA vasculitis (IgAV) is more common in males, but the potential impact of gender remains unclear. We aimed to describe the impact of gender on presentation and outcome in adult IgAV.
Methods: We retrospectively analysed data from a multicentre retrospective cohort of 260 patients (IGAVAS).
The question of an increased cardiovascular risk has been recently raised in adults with phenylketonuria (PKU). As low-grade systemic inflammation increases cardiovascular risk, the INGRAPH study aimed to evaluate low-grade inflammation in adult PKU patients compared to healthy controls and to determine the potential influence of Phe-controlled diet on inflammation. Twenty early-treated adult PKU patients, including a subgroup of 15 classical PKU patients, and 20 healthy volunteers were included.
View Article and Find Full Text PDFInborn metabolic diseases (IMD) are rare conditions that can be diagnosed during adulthood. Patients with IMD may have joint symptoms and the challenge is to establish an early diagnosis in order to institute appropriate treatment and prevent irreversible damage. This review describes the joint manifestations of IMD that may be encountered in adults.
View Article and Find Full Text PDFIgA vasculitis (IgAV) is a small size vasculitis for which epidemiologic data are strikingly lacking, especially about the adult form. Additionally, the COVID-19 pandemic seems to have profoundly modified the incidence of this disease. Here, we aimed to establish some relevant epidemiological data in both pediatric and adult IgAV.
View Article and Find Full Text PDFArticle Synopsis
- A study compared two ways of giving a medicine called tocilizumab to patients with a disease called Takayasu arteritis (TAK).
- They looked at 109 patients from different countries and found that both methods worked similarly well after 6 months, with about 69% showing improvement.
- However, patients who got tocilizumab as a shot under the skin had a higher chance of getting worse again compared to those who received it through an IV.
Introduction: Rituximab is a chimeric anti-CD20 antibody commonly used to treat patients with autoimmune diseases. Such diseases mainly affect young people, but older patients may also be concerned. So far, very little data exist concerning the safety of rituximab in older patients with autoimmune diseases.
View Article and Find Full Text PDFObjective: IgA vasculitis (IgAV) can occur after vaccination. We aimed to assess a potential safety signal on the association between coronavirus disease 2019 (COVID-19) vaccines and IgAV.
Methods: Cases of IgAV involving COVID-19 vaccines were retrieved in VigiBase.
Background: The vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a newly identified autoinflammatory disorder related to somatic UBA1 mutations. Up to 72% of patients may show lung involvement.
Research Question: What are the pleuropulmonary manifestations in VEXAS syndrome?
Study Design And Methods: One hundred fourteen patients were included in the French cohort of VEXAS syndrome between November 2020 and May 2021.
Objective: Immunoglobulin A vasculitis (IgAV) usually occurs following viral respiratory tract infection. In the context of the global coronavirus disease 2019 (COVID-19) pandemic, we describe a case series of patients who developed IgAV following SARS-CoV-2 infection.
Methods: This national multicenter retrospective study included patients with IgAV following SARS-CoV-2 infection from January 1, 2020, to January 1, 2022.
Article Synopsis
- Researchers tested whether anakinra, a drug for blocking interleukin-1 receptors, could help moderate COVID-19 patients requiring oxygen treatment.
- In a trial with 71 enrolled patients, those receiving anakinra had lower treatment success and higher mortality at 28 days compared to those receiving standard care.
- The study concluded that anakinra was not effective and even proved to be worse than standard care for treating moderate COVID-19 pneumonia.
Anti-U1-RNP antibodies are necessary for the diagnosis of mixed connective tissue disease (MCTD), but they are also prevalent in other connective tissue diseases, especially systemic lupus erythematosus (SLE), from which distinction remains challenging. We aimed to describe the presentation and outcome of patients with anti-U1-RNP antibodies and to identify factors to distinguish MCTD from SLE. We retrospectively applied the criteria sets for MCTD, SLE, systemic sclerosis (SSc) and rheumatoid arthritis (RA) to all patients displaying anti-U1-RNP antibodies in the hospital of Caen from 2000 to 2020.
View Article and Find Full Text PDFObjective: There is currently no evidence of the possible benefit of plasma cell-targeting therapies (PCTT) in immunoglobulin A (IgA) monoclonal gammopathy (MG) associated with IgA vasculitis (IgAV). We report the outcome of different PCTT regimens in a cohort of MG-IgAV.
Methods: We used a French network to retrospectively describe the outcome of MG-IgAV patients treated with PCTT.